Wall Street brokerages predict that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will post sales of $1.59 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for ZIOPHARM Oncology’s earnings, with the highest sales estimate coming in at $1.70 million and the lowest estimate coming in at $1.46 million. ZIOPHARM Oncology posted sales of $1.60 million during the same quarter last year, which would indicate a negative year over year growth rate of 0.6%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 15th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full-year sales of $1.59 million for the current year, with estimates ranging from $6.26 million to $7.00 million. For the next year, analysts expect that the firm will report sales of $5.41 million per share, with estimates ranging from $3.00 million to $6.40 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same period in the previous year, the firm earned ($0.11) EPS. The business’s revenue was up .0% on a year-over-year basis.
In related news, CEO Laurence James Neil Cooper purchased 6,440 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology in the third quarter valued at about $104,000. Amalgamated Bank lifted its position in shares of ZIOPHARM Oncology by 12.9% in the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,924 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of ZIOPHARM Oncology by 50.0% in the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 6,000 shares in the last quarter. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology in the second quarter valued at about $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new position in shares of ZIOPHARM Oncology in the third quarter valued at about $141,000. 40.23% of the stock is owned by institutional investors and hedge funds.
Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at $4.16 on Friday. ZIOPHARM Oncology has a fifty-two week low of $3.90 and a fifty-two week high of $7.88.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.